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Abstract
Background: European guidelines on primary prevention of cardiovascular disease (CVD) recommend the SCORE
risk charts for determining CVD risk, which include blood pressure and serum cholesterol as risk parameters. To
facilitate cost-effective large-scale screening, we aimed to construct a risk score with ‘non-invasive’ parameters as a
first screening step to identify persons at increased CVD risk requiring further risk assessment.
Methods: We used data of Dutch employees from 25 organisations participating in a health risk assessment
between August 2007 and January 2013. Backward multivariate logistic regression analysis was employed to select
non-invasive, independent predictors of high CVD risk, defined as the 10-year risk of fatal CVD of ≥5 % based on
the SCORE formula. The total CVD risk score was calculated as the summed coefficients of the retained variables.
Results: Data of 6189 male participants was used for the development and validation of the risk score. Age, tobacco use,
history of hypertension, alcohol consumption, BMI, and waist circumference were independent predictors of high CVD
risk. Ten-fold cross-validation resulted in an area under the curve of 0.95 (SE 0.01, 95 % confidence interval 0.94–0.96). A
cut-off score ≥45 on the CVD risk score yielded a sensitivity of 0.93, and a specificity of 0.85.
Conclusions: We developed a simple, non-invasive risk score that accurately identifies persons at increased CVD risk
according to the SCORE formula in a population of working men. The risk score enables a stepwise approach in large
screening programmes, strongly reducing the number of persons that require full risk estimation including blood pressure
and cholesterol measures.
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Background
Cardiovascular disease (CVD) is the major cause of pre-
mature death in Europe [1, 2]. Despite the identification
of modifiable risk factors such as smoking, sedentary life-
style, blood pressure (BP) and dyslipidemia [3], prevention
of CVD remains challenging. A complicating factor is that
treatable cardiovascular risk factors can be silently present
for many years before detection by routine check-up or
the occurrence of a cardiovascular event.
Early detection of individuals at high CVD risk is the
cornerstone of primary prevention. For estimation of
CVD risk current guidelines from the joint task force of
the European Association for Cardiovascular Prevention
and Rehabilitation [4] recommend the use of the SCORE
(Systemic COronary Risk Evaluation) risk estimation [5].
Based on age, gender, smoking status, cholesterol and
BP an estimation of the 10-year risk of dying from CVD
can be calculated, or derived from a risk chart. The risk
estimation is used to offer the individual tailored health
advice, including behavioural strategies to improve
lifestyle and pharmacological interventions aimed at
reducing BP and cholesterol. For practical reasons it
is currently recommended to assess cardiovascular
risk in all men over 40 and women over 50 years of
age or post-menopausal without CVD [6]. However,
population-wide screening of all persons meeting these
criteria is a very costly and time-consuming effort, mak-
ing it an unattractive approach for everyday practice [7].
The use of a simple, non-invasive risk score based on
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current guideline recommendations as a first step in the
screening process might overcome these barriers and fa-
cilitate large scale CVD screening. Such a risk score can
be used to select individuals who are likely to be at high
CVD risk after performing a full SCORE risk estimation
including BP measurements and blood sampling, thereby
significantly reducing the costs and labour-intensiveness
for CVD screening. Risk scores have been developed to
identify patients at increased risk for diabetes [8–10],
kidney disease [11], or a combination of cardiometabolic
endpoints [12], but not for CVD risk estimation accord-
ing to the SCORE equation.
In the present study, our aim was therefore to facilitate
cardiovascular screening in primary care according to
current European guidelines by developing a CVD risk
score using simple, non-invasive parameters to identify
persons at high CVD risk according to SCORE risk esti-
mation. To this end, we used the data of a large web-




The current study was performed as part of a worksite
HRA implemented in Dutch organisations between
August 2007 and January 2013. Study participants were
employees aged 40–70 years that completed the HRA
within this timeframe. Pregnant woman were excluded
from enrolling in the HRA. Because the prediction tool
was aimed at identifying previously undetected persons
at high CVD risk, employees with established CVD or
on current treatment for hypertension, hypercholester-
olemia, diabetes or chronic kidney disease were ex-
cluded from analysis. Informed consent was obtained
from all participants prior to the study in accordance with
the requirements for identifiable data collection in the




Details of the HRA have been described previously [13].
In brief, invitations to participate in the HRA were sent
by the human resources department, management, or
the safety, health, and welfare services of the organiza-
tions involved. The invitation included a description of
the HRA and informed employees that participation was
voluntary and free of charge, that all personal data
would be treated confidentially, and that no individual
results would be shared with their employer or any other
party.
Attendees completed a web-based electronic health
questionnaire which included ~100 questions covering
socio-demographics, personal health history, family risk
and the behavioural domain. This was followed by bio-
metric measurements including length, weight and waist
circumference conducted at the worksite by certified
staff. Two BP measurements were taken after 5 min of
relaxation with a validated oscillometric device. If both
systolic measurements were below 140 mmHg, the mean
was used for analyses. When at least one of the systolic
readings was ≥140 mmHg, participants were instructed
to relax for another 30 min in a secluded area after
which a third BP measurement was taken. The mean of
all three measurements was then used for analyses. At the
same visit blood samples were collected for determination
of total cholesterol, HDL-cholesterol, LDL-cholesterol, tri-
glycerides, glucose, creatinine, and HbA1C. Creatinine
was used to calculate the estimated glomerular filtration
rate according to the CKD-EPI formula [14], and is
expressed in mL/min per 1.73 m2. A urine sample was de-
tected to assess the albumin/creatinine ratio (ACR). In-
creased ACR was defined as ≥3.5 for male, and ≥2.5 for
female persons. A personalised web-based health report
and health plan was automatically generated when all
health data were collected after which the HRA was
completed.
Assessment of CVD mortality risk
CVD mortality risk was assessed according to the
SCORE risk estimation. The SCORE risk estimation pre-
dicts the 10-year risk of dying from CVD based on data
of 12 large European cohort studies [5]. Variables in the
SCORE risk estimation include age, gender, current
smoking status, systolic BP (mmHg), and total choles-
terol (mmol/L) or the total cholesterol/HDL ratio. In the
current study we used total cholesterol to calculate
SCORE. Because current guidelines recommend to offer
health advice and consider medical treatment in persons
with a predicted 10-year CVD mortality risk of ≥5 %,
this threshold was used for our primary analysis [1]. The
Netherlands constitutes a low risk region in terms of
CVD mortality, therefore the SCORE risk formula for
low risk regions was used [5].
Potential predictor variables
For the development of the screening tool, non-
invasively assessed variables with a possible association
with CVD risk were selected from the HRA. This selec-
tion was independently carried out by two physicians
(NvdH and DES). Disagreement between the two physi-
cians was resolved through discussion moderated by a
specialist in cardiovascular medicine (BJvdB), who gave
the decisive vote. A total of 23 non-invasively assessed
variables were selected as potential predictors for CVD.
Date of birth, gender, marital status, education and
ethnicity were selected from questions related to socio-
economic status. For marital status, participants selected
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one of six categories. Education level was defined as the
highest education completed and was stratified in three
categories, low (lower general secondary and lower voca-
tional), middle (higher general secondary, pre-university
and intermediate vocational), and high (higher vocational,
university and doctorate). Ethnicity was defined according
to parental background. As the majority of participants
were of European descent, the non-European descent an-
swer categories were merged into “other”.
Self-rated health was assessed, as previously described,
by the question “How do you rate your health in general?”,
and categorised in strata ranging from poor to very good
[15, 16]. Frequency of tobacco use was stratified in none,
occasionally, weekly, or daily. Alcohol consumption was
reported according to the Dutch Municipal Health Service
questionnaire, which records the number of consumed al-
cohol units per week using a semi-quantitative scale. Low
vegetable and fruit intake was defined as an average con-
sumption of less than 3 tablespoons of vegetables or 2
pieces of fruit per day. Fat intake was estimated based on
the daily consumption of butter, margarine, cheese and
other sandwich fillings. Low fish consumption was defined
as less than 1 fish meal per week. In accordance with the
INTERHEART study [17], two items relating to stress at
home and stress at work were combined into a general
stress scale and graded as follows: 1) never experienced
stress; 2) experienced some periods at home or work; 3)
experienced several periods at home or work; 4) experi-
enced permanent stress at home or work. Physical activity
was self-assessed by one item derived from the Dutch ver-
sion of the International Physical Activity Questionnaire
(IPAQ) [18]. Participants entered the number of weekdays
on which they spent at least 30 min on moderate to vigor-
ous physical activity. Moderate physical activity includes
activity that increases respiratory rate, but still allows a
person to talk, such as taking a firm walk, swimming, or
gardening. Vigorous physical activity includes activity
which increases respiratory rate to a level at which a per-
son cannot easily talk anymore, such as intensive exercise,
running, or cycling with a speed of ≥17 km/h. Distress
was self-assessed with the validated Dutch version of the
Extended Kessler distress scale (EK-10) [19, 20], ranging
from 10 (no distress) to 50 (severe distress) with a cut-off
score of ≥20. First degree family history of CVD (diagnosed
before age 60), diabetes mellitus and hypertension was self-
reported. History of diabetes mellitus, hypertension, hyper-
cholesterolemia, renal insufficiency was assessed by asking
if participants were ever treated for diabetes, blood pres-
sure, high cholesterol or renal insufficiency. Subsequently,
persons were asked whether they were still using medica-
tion for the selected condition(s). Mental health problems
were considered present if participants received treatment
for a mental health disorder, such as depression or anxiety.
Self-reported length and weight were used to calculate body
mass index (BMI) which was categorised into normal (BMI
<25 kg/m2), overweight (BMI ≥25 and <30 kg/m2) and
obese (BMI ≥30 kg/m2). A waist circumference of ≥94 cm
for men and ≥80 cm for women was considered indicative
of the presence of visceral adiposity.
Statistical analysis
Descriptive statistics were used to present the baseline
characteristics of the study population. Univariate logistic
regression was performed to determine the single effects
of potential predictors on a CVD mortality risk of ≥5 %.
Variables with a p-value <0.10 in the univariate logistic
models were entered in the multivariate model. After step-
wise backward elimination of predictors the final model
included variables with a p-value of <0.05. Continuous
variables were categorised to simplify its use. The total
CVD risk score was calculated as the summed coefficients
of the retained variables. Area under the curve (AUC)
analysis was used as a measure of overall test perform-
ance. An AUC of ≥0.80 is considered indicative of a useful
screening instrument [21]. Sensitivity, specificity, positive
predictive value, negative predictive value, positive likeli-
hood ratio and negative likelihood ratio were calculated at
various cut-off values on the total CVD risk score. All ana-
lyses were performed using IBM SPSS version 19 (SPSS
Inc., Chicago, Illinois, USA). The data was openly available
to the authors during the study time. All interested parties
can obtain the data needed to replicate the findings upon
request. Parties can contact Dr R.A. Kraaijenhagen
(r.a.kraaijenhagen@niped.nl) for these requests.
Internal validation
K-fold cross-validation was performed in which 10
multivariate models were developed on one part of the
data (90 %) and validated on the independent part
(10 %). The advantage of K-fold cross validation is that
all the cases in the dataset are consecutively used for
both model development and validation. The average
performance of the models was calculated using AUC.
Stepwise backward selection of variables was applied in
every training sample [22, 23].
Results
There were 11,407 employees from 25 organisations
who completed the HRA during the study period. A
total of 1653 participants (14.5 %) met one or more ex-
clusion criteria. Baseline characteristics of the 9784 in-
cluded participants are described in Table 1. In total,
4.3 % of men and 0.2 % of women had a SCORE esti-
mated CVD risk ≥5 %. Because the number of women
with a SCORE ≥5 % was too low to produce a model of
valid statistical inference (n = 8), we proceeded to de-
velop a prediction model for men [24].
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Model development
In univariate analysis, 12 of the 23 selected variables
were predictive of the SCORE estimated CVD risk ≥5 %
threshold (Additional file 1: Table S1) and subsequently
entered in the multivariate analysis. Table 2 shows the
six variables retained in the final model. Age, tobacco
use, self-reported history of hypertension (without
current treatment), alcohol consumption, BMI and ab-
dominal obesity independently predicted a ≥5 % SCORE
risk. To facilitate practical use of the CVD risk score, β’s
of these variables were multiplied and rounded to the
nearest integer. A multiplication factor of 7 was chosen
to sustain sufficient discriminative power between differ-
ent predictor variables, resulting in a total CVD risk
score ranging from 0 to 96.
Model validation
Ten-fold cross-validation resulted in an AUC of 0.95
(95 % CI [0.94–0.95]), demonstrating good discrimin-
atory power. Diagnostic classification accuracy of the
risk score at multiple cut-off values is shown in Table 3.
To illustrate the influence of individual parameters on
the outcome of the model several case examples are
depicted in Table 4 using a cut-off value of ≥45. At this
Table 1 Baseline characteristics of study sample (n = 9784)
Men (n = 6189) Women (n = 3565)
Age (SD) 49.4 6.0 47.1 5.5
Educationa
Low (%) 973 15.7 1030 28.9
Middle (%) 1988 32.1 1430 40.1
High (%) 3228 52.2 1105 31.0
Ethnicity
Caucasian (%) 5821 94.1 3187 89.4
Other (%) 368 5.9 378 10.6
Tobacco use
None (%) 5294 85.5 2977 83.5
At least once a week (%) 469 7.6 251 7.0
At least 10 g per day (%) 426 6.9 337 9.5
Body mass index (SD) 25.7 3.2 24.7 4.1
BMI <25 (%) 2738 44.2 2202 61.8
Overweight: BMI ≥25 - <30 (%) 2923 47.2 988 27.7
Obese: BMI ≥30 (%) 528 8.5 375 10.5
Serum total cholesterol in mmol/l (SD) 5.8 1.0 5.5 1.0
History of hypercholesterolemia (%) 179 2.9 58 1.6
Systolic blood pressure in mmHg (SD) 135.9 16.2 126.9 17.0
History of hypertension (%) 207 3.3 155 4.3
History of diabetes mellitus (%) 19 0.3 13 0.4
SCORE-low risk 5–10 (%) 235 3.8 7 0.1
SCORE-low risk >10 (%) 31 0.5 1 0.0
History of renal insufficiency (%) 72 1.2 29 0.8
eGFR (mL/min per 1.73 m2)
≥ 90 (%) 3363 54.3 1822 51.1
60–90 (%) 2678 43.3 1612 45.2
45–59 (%) 143 2.3 127 3.6
30–44 (%) 5 0.1 4 0.1
< 30 (%) 0 0 0 0
Increased ACR (%) 109 1.8 70 2.0
aEducation level. Low: lower general secondary/lower vocational. Middle: higher general secondary/pre-university/ intermediate vocational. High:
Higher vocational/university/doctorate
eGFR: estimated glomerular filtration rate based on the chronic kidney disease epidemiology collaboration (CKD-EPI) formula. ACR: albumin/creatinine ratio in
urine. Increased values defined as ≥3.5 for male and ≥2.5 for female persons
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cut-off, 18 % of the study population has an estimated
CVD risk ≥5 %.
Discussion
We developed and validated a simple six-item CVD risk
score that can be used as a first step in identifying male
employees at high CVD risk based on current European
guidelines using the SCORE risk estimation. At a cut-off
of ≥45, only 18 % of screened persons where qualified as
high CVD risk requiring further risk assessment, with a
false-negative rate of 7 %. Because of the low prevalence
of women with increased cardiovascular risk before age
65, screening women for CVD in the context of a work-
site HRA does not seem to be efficacious.
Our proposed CVD risk score is developed to facilitate
large scale CVD screening programmes based on the
current guidelines by offering an easy and highly accurate
first step in the screening process [4]. Instead of applying
full CVD screening with BP measurement and blood sam-
pling to all men aged 40 years and above, the CVD risk
score can be used to preselect persons who require a total
risk estimation. Applying this stepped approach means
that BP and cholesterol measurement is required in only a
small fraction of the screened population. The CVD risk
score therefore seems a useful tool in reducing the costs,
means and time needed to perform large scale screening.
Choosing the cut-off value on the CVD risk score is a
matter of policy and dependent on the acceptable percent-
age of false negatives and false positives in a particular
screening setting. The high accuracy of our screening tool,
however, seems to provide an acceptable trade-off be-
tween both rates.
Although we emphasize that ideally – as recommended
in current guidelines - a full risk estimation is performed
Table 2 Multivariate regression of high cardiovascular disease risk in men for sociodemographic, lifestyle, and biometric variables (n= 6189)
SCORE risk ≥5 %a
95.0 % C.I.
Odds Ratio Lower Upper β Risk Scoreb
Age 40–49c 0
50–54 15.517 4.644 51.844 2.742 19
55–59 206.816 64.758 660.507 5.332 37
60–70 1168.532 354.895 3847.520 7.064 49
Tobacco use Nonec 0
At least once a week 14.232 9.977 20.300 2.655 19
Alcohol <1 units per weekc 0
Consumption 1–7 units per week 1.142 .688 1.895 .132 1
8–14 units per week 1.278 .753 2.170 .246 2
15–21 units per week 2.035 1.135 3.648 .710 5
≥22 units per week 2.376 1.295 4.360 .866 6
Body mass index Normal weight: BMI <25 kg/m2c 0
(BMI) Overweight: BMI≥ 25 - <30 kg/m2 1.687 1.130 2.520 .523 4
Obese: BMI ≥30 kg/m2 1.932 1.043 3.579 .659 5
Waist circumference <94 cm 0
≥94 cm 1.849 1.238 2.760 .615 4
History of hypertension No 0
Yes 6.158 3.551 10.680 1.818 13
aBased on the SCORE equation for countries with low cardiovascular risk
bThe risk score is produced by multiplying β’s by 7 and rounding them to the nearest integer
cindicates reference category
Table 3 Diagnostic classification accuracy of predicting high CVD risk at different cut-off values
TP FN FP TN Sensitivity Specificity PPV LR + LR-
Cut-off ≥40 254 12 1181 4742 95.5 % 80.1 % 17.7 % 4.8 0.1
Cut-off ≥45 247 19 888 5035 92.9 % 85.0 % 21.8 % 6.2 0.1
Cut-off ≥50 198 68 438 5485 74.4 % 92.6 % 31.1 % 10.1 0.3
CVD cardiovascular disease, TP true positive, FN false negative, FP false positive, TN true negative, PPV positive predictive value, LR+ positive likelihood ratio,
LR- negative likelihood ratio
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in every eligible person, most practices lack the time or fi-
nances to do so [7]. In such situations our CVD risk score
can be employed instead as a first step in the risk assess-
ment. A possible pitfall of using the CVD risk score com-
pared to the original SCORE risk estimate, is that
individuals who are at increased CVD risk because of iso-
lated highly elevated BP or cholesterol could be missed as
both are not measured. Other important cardiovascular
risk factors such as diabetes or chronic kidney disease are
not included in the SCORE formula, and persons with
these risk factors could also be missed. However, this only
applies to persons with risk factors that are untreated, as
we excluded persons on current treatment for hyperten-
sion, hypercholesterolemia, diabetes, or chronic kidney
disease because they are already at increased CVD risk.
The number of persons with untreated risk factors is likely
to be small in a relatively healthy working population. This
is supported by the fact that in our population the number
of subjects with moderate to severe renal function (eGFR
< 45 ml/min/1.73 m2) was only 0.1 %. Nonetheless, be-
cause the proposed screening strategy is based on the
identification of patients at risk for CVD with a simple
questionnaire persons with these risk factors could remain
unidentified. This should be taken in consideration when
using the CVD risk score.
The performance of the original SCORE risk ranges
from reasonable to good (AUC 0.71–0.84) [5]. Our CVD
risk score is likely to resemble this performance, given
its high accuracy in predicting the 10-year mortality risk
of ≥5 %. Age and tobacco conferred the largest predict-
ive value in our proposed risk score which is not surpris-
ing as they are both included in the SCORE risk
assessment. Next to these variables, alcohol consump-
tion, BMI, waist circumference and a history of hyper-
tension (but currently untreated) independently
predicted ≥5 % SCORE risk. It is likely that they act as a
surrogate for the remaining SCORE variables, systolic
BP and total cholesterol. High BMI and a large waist cir-
cumference often coincide with a high BP or dyslipid-
emia as part of the metabolic syndrome [25]. A history
of hypertension indicates that the person has or is prone
to develop hypertension. Although alcohol consumption
might even be protective for development of the meta-
bolic syndrome [26], there is a positive correlation be-
tween alcohol consumption and increased BP [27]. The
contribution to the CVD risk score of these four vari-
ables is smaller than age and tobacco, but still these vari-
ables can be decisive in determining the screening
outcome. In addition, these variables can also be used
for a tailored lifestyle advice.
The low prevalence of women that reached the ≥5 %
SCORE threshold in the current study population is in
line with findings of a previous study comprising two
Dutch population cohorts of similar age as the current
population [28], where 0.1 % of the women and 3.1 % of
the men reached the ≥5 % SCORE threshold. These
findings are not surprising given that the ≥5 % threshold
for low risk countries is not reached for non-smoking
women until the age of 65, or 60 for smoking women, ir-
respective of BP or cholesterol [5]. Based on these num-
bers screening for CVD in women aged <60 years seems
not useful from a worksite health care perspective in
low-risk countries.
There are several limitations to our study that need
further consideration. First, the proposed CVD risk
score is developed and validated in a cohort of em-
ployees, which possibly limits the external validity of the
screening tool when used in the general population.
Nonetheless, the workplace provides an ideal setting for
CVD risk screening as most men in the targeted age
range (40–70) are part of the working population, and
because it can facilitate the creation of a health-
conscious environment [29]. Second, we did not include
sedentary lifestyle in the questionnaire of our HRA.
Sedentary lifestyle is one of the major risk factors for
CVD [30], and inclusion of this non-invasive parameter
to our questionnaire could have further increased the
accuracy of our CVD risk score. Third, we have no data
on CVD outcome in our population. As the aim of the
study was to build a model to identify subjects with high















1 52 No 8–14 ≥25– <30 <94 cm No 25 No
2 52 Yes 15–21 ≥25– <30 ≥94 cm No 51 Yes
3 57 No 8–14 ≥25– <30 <94 cm No 43 No
4 57 Yes <1 <25 <94 cm No 56 Yes
5 47 Yes 15–21 ≥30 ≥94 cm No 33 No
6 57 No 1–7 <25 <94 cm Yes 51 Yes
7 62 No <1 <25 <94 cm No 49 Yes
BMI body mass index
abased on a cut-off of ≥45 points
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SCORE risk, in line with current guideline recommen-
dations, these data were not required. It would be, how-
ever, interesting in future research to validate the model
on actual CVD outcome. F, the proposed CVD risk
score can only be used in countries with low CVD
population risk. However, the methods described in the
current study can also be used to develop a similar
model for high-risk countries. Finally, the proposed
CVD risk score includes self-reported length and
weight, which could lead to a slight underestimation of
the calculated BMI [31].
Conclusion
In conclusion, we used the data of a health risk assessment
conducted in 25 Dutch organisations to construct a pro-
posal for a simple six-item CVD risk score to identify indi-
viduals at increased CVD risk as defined by the SCORE
risk estimation. The present risk score can be offered online
as a simple, quick and inexpensive first step in the identifi-
cation of persons at high cardiovascular risk, who subse-
quently qualify for further risk profiling according to the
SCORE formula, including BP and cholesterol measures.
We designed and validated our tool in population of
workers from a European country at low CVD risk. Future
studies should investigate whether the newly developed risk
score can also be applied for other populations. Studies
implementing our screening tool are warranted to evaluate
the cost-effectiveness of a stepped approach for CVD risk
screening as part of primary prevention strategies.
Additional file
Additional file 1: Table S1. Univariate regression of high cardiovascular
disease risk in men for sociodemographic, lifestyle and biometric
variables. (DOC 106 kb)
Competing interests
RK is one of the directors and co-owners of NIPED Prevention. This institute
developed the worksite health promotion program described in the current
manuscript. MN is full-time and NvdH is part-time employed as researcher by
NIPED Research Foundation. No other relationships or activities could appear
to have influenced the submitted work.
Authors’ contributions
NvdH prepared the manuscript (in collaboration with MN), helped with the
data-analysis and interpreted the results. MN prepared the manuscript (in
collaboration with NvdH), helped with the study design, performed the
data-analysis and interpreted the results. ES critically reviewed and revised
the manuscript. LB helped with the study design and data-analyses and critically
reviewed the paper. RK designed the study, supervised the data-analysis and
critically reviewed the paper. BvdB supervised the manuscript preparation, helped
with interpretation of the results and critically reviewed the paper. All authors have
read and approved the final manuscript.
Acknowledgements
We thank D.W. Eeftinck Schattenkerk, MD for his help with the selection of
the predictor variables.
Source(s) of funding
All authors declare they have received no support from any organization for
the submitted work.
Author details
1Departments of Internal and Vascular Medicine, Academic Medical Center of
the University of Amsterdam, Meibergdreef 9, 1105AZ Amsterdam, The
Netherlands. 2NIPED Research Foundation, Amsterdam, The Netherlands.
3Department of Public Health, Erasmus MC, Rotterdam, The Netherlands.
Received: 26 June 2015 Accepted: 20 October 2015
References
1. European Heart Network. European Cardiovascular Disease Statistics.
2008th ed. 2012.
2. Levi F, Chatenoud L, Bertuccio P, Lucchini F, Negri E, La VC. Mortality from
cardiovascular and cerebrovascular diseases in Europe and other areas of
the world: an update. Eur J Cardiovasc Prev Rehabil. 2009;16(3):333–50.
3. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of
potentially modifiable risk factors associated with myocardial infarction in
52 countries (the INTERHEART study): case–control study. Lancet.
2004;364(9438):937–52.
4. Perk J, De Backer G, Gohlke H, Graham I, Reiner Z, Verschuren M, et al.
European Guidelines on cardiovascular disease prevention in clinical
practice (version 2012): the Fifth Joint Task Force of the European Society of
Cardiology and Other Societies on Cardiovascular Disease Prevention in
Clinical Practice (constituted by representatives of nine societies and by
invited experts). Eur J Prev Cardiol. 2012; 19(4):585–667.
5. Conroy RM, Pyorala K, Fitzgerald AP, Sans S, Menotti A, De BG, et al.
Estimation of ten-year risk of fatal cardiovascular disease in Europe: the
SCORE project. Eur Heart J. 2003;24(11):987–1003.
6. Reiner Z, Catapano AL, De BG, Graham I, Taskinen MR, Wiklund O, et al. ESC/
EAS Guidelines for the management of dyslipidaemias: the Task Force for
the management of dyslipidaemias of the European Society of Cardiology
(ESC) and the European Atherosclerosis Society (EAS). Eur Heart J.
2011;32(14):1769–818.
7. Graham IM, Stewart M, Hertog MG. Factors impeding the implementation
of cardiovascular prevention guidelines: findings from a survey conducted
by the European Society of Cardiology. Eur J Cardiovasc Prev Rehabil.
2006;13(5):839–45.
8. Lindstrom J, Tuomilehto J. The diabetes risk score: a practical tool to predict
type 2 diabetes risk. Diabetes Care. 2003;26(3):725–31.
9. Schmidt MI, Duncan BB, Bang H, Pankow JS, Ballantyne CM, Golden SH, et
al. Identifying individuals at high risk for diabetes: The Atherosclerosis Risk in
Communities study. Diabetes Care. 2005;28(8):2013–8.
10. Schulze MB, Hoffmann K, Boeing H, Linseisen J, Rohrmann S, Mohlig M, et
al. An accurate risk score based on anthropometric, dietary, and lifestyle
factors to predict the development of type 2 diabetes. Diabetes Care.
2007;30(3):510–5.
11. Kshirsagar AV, Bang H, Bomback AS, Vupputuri S, Shoham DA, Kern LM, et
al. A simple algorithm to predict incident kidney disease. Arch Intern Med.
2008;168(22):2466–73.
12. Alssema M, Newson RS, Bakker SJ, Stehouwer CD, Heymans MW, Nijpels G,
et al. One risk assessment tool for cardiovascular disease, type 2 diabetes,
and chronic kidney disease. Diabetes Care. 2012;35(4):741–8.
13. Niessen MAJ, Kraaijenhagen RA, Dijkgraaf MG, Van PD, Van Kalken CK, Peek
N. Impact of a Web-based worksite health promotion program on
absenteeism. J Occup Environ Med. 2012;54(4):404–8.
14. Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro III AF, Feldman HI, et al.
A new equation to estimate glomerular filtration rate. Ann Intern Med.
2009;150(9):604–12.
15. Fayers PM, Sprangers MA. Understanding self-rated health. Lancet.
2002;359(9302):187–8.
16. Mavaddat N, Kinmonth AL, Sanderson S, Surtees P, Bingham S, Khaw KT.
What determines Self-Rated Health (SRH)? A cross-sectional study of SF-36
health domains in the EPIC-Norfolk cohort. J Epidemiol Community Health.
2011;65(9):800–6.
17. Rosengren A, Hawken S, Ounpuu S, Sliwa K, Zubaid M, Almahmeed WA,
et al. Association of psychosocial risk factors with risk of acute myocardial
van der Hoeven et al. BMC Cardiovascular Disorders  (2015) 15:140 Page 7 of 8
infarction in 11119 cases and 13648 controls from 52 countries
(the INTERHEART study): case–control study. Lancet. 2004;364(9438):953–62.
18. Craig CL, Marshall AL, Sjostrom M, Bauman AE, Booth ML, Ainsworth BE,
et al. International physical activity questionnaire: 12-country reliability and
validity. Med Sci Sports Exerc. 2003;35(8):1381–95.
19. Donker T, Comijs H, Cuijpers P, Terluin B, Nolen W, Zitman F, et al. The
validity of the Dutch K10 and extended K10 screening scales for depressive
and anxiety disorders. Psychiatry Res. 2010;176(1):45–50.
20. Kessler RC, Andrews G, Colpe LJ, Hiripi E, Mroczek DK, Normand SL, et al.
Short screening scales to monitor population prevalences and trends in
non-specific psychological distress. Psychol Med. 2002;32(6):959–76.
21. Means-Christensen AJ, Arnau RC, Tonidandel AM, Bramson R, Meagher MW.
An efficient method of identifying major depression and panic disorder in
primary care. J Behav Med. 2005;28(6):565–72.
22. Refaeilzadeh P, Tang L, Liu H. Cross-Validation. In: Liu L, Ozsu MT, editors.
Encyclopedia of Database Systems. 2009. p. 532–8.
23. Steyerberg EW, Harrell Jr FE, Borsboom GJ, Eijkemans MJ, Vergouwe Y,
Habbema JD. Internal validation of predictive models: efficiency of some
procedures for logistic regression analysis. J Clin Epidemiol. 2001;54(8):774–81.
24. Bagley SC, White H, Golomb BA. Logistic regression in the medical literature:
standards for use and reporting, with particular attention to one medical
domain. J Clin Epidemiol. 2001;54(10):979–85.
25. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet.
2005;365(9468):1415–28.
26. Freiberg MS, Cabral HJ, Heeren TC, Vasan RS, Curtis ER. Alcohol
consumption and the prevalence of the Metabolic Syndrome in the US.: a
cross-sectional analysis of data from the Third National Health and Nutrition
Examination Survey. Diabetes Care. 2004;27(12):2954–9.
27. Puddey IB, Beilin LJ, Rakie V. Alcohol, hypertension and the cardiovascular
system: a critical appraisal. Addicition Biol. 1997;2(2):159–70.
28. Van Dis I, Kromhout D, Geleijnse JM, Boer JM, Verschuren WM. Evaluation of
cardiovascular risk predicted by different SCORE equations: the Netherlands
as an example. Eur J Cardiovasc Prev Rehabil 2010;17:244-249.
29. Niessen MA, Laan EL, Robroek SJ, Essink-Bot ML, Peek N, Kraaijenhagen RA,
et al. Determinants of participation in a web-based health risk assessment
and consequences for health promotion programs. J Med Internet Res.
2013;15(8):e151.
30. Warren TY, Barry V, Hooker SP, Sui X, Church TS, Blair SN. Sedentary
behaviors increase risk of cardiovascular disease mortality in men. Med Sci
Sports Exerc. 2010;42(5):879–85.
31. Nyholm M, Gullberg B, Merlo J, Lundqvist-Persson C, Rastam L, Lindblad U. The
validity of obesity based on self-reported weight and height: Implications for
population studies. Obesity (Silver Spring). 2007;15(1):197–208.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
van der Hoeven et al. BMC Cardiovascular Disorders  (2015) 15:140 Page 8 of 8
